Brain
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A071102
Primary Category:
Treatment Protocols
A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant
Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Alliance A071102 is permanently closed to new patient registration (Step 1) effective October 15, 2018.
NCT#02152982
(Click for More Info)
ALLIANCE A071401
Primary Category:
Treatment Protocols
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations
NCT#02523014
(Click for More Info)
A071401 Cohorts NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) are closed to new patient registration (Step 1) to abemaciclib cohort, effective October 3, 2022.
ALLIANCE A071601
Primary Category:
Treatment Protocols
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
NCT#03224767
(Click for More Info)
ALLIANCE A071701
Primary Category:
Treatment Protocols
Disease Category:
Brain, Brain Metastatic, Molecular Profiling
Genomically-Guided Treatment Trial in Brain Metastases
(Click for More Info)
ALLIANCE A071702
Primary Category:
Treatment Protocols
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma
(Click for More Info)
NCT#04145115
ALLIANCE A071801
Primary Category:
Radiation Oncology
Disease Category:
Brain, Brain Metastatic
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
Eligible for screening study DCP 001
NCT#04114981
(Click for More Info)
A071801 is permanently closed to accrual, effective September 9, 2022 at 4:30 pm ET.
ALLIANCE CCTG CE.7
Primary Category:
Radiation Oncology
Disease Category:
Brain, Brain Metastatic
A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases
Eligible for screening study DCP 001
For CCTG CE.7, please credit ALLIANCE all accruals.
NCT#03550391
(Click for More Info)
CCTG CE.7 has reopened with Amendment 1 to resume patient accrual at your center, your site will be required to provide confirmation of HA-WBRT credentialing and approval by IROC.
Protocol Consent Schema Eligibility & Calendar
ALLIANCE N0577
Primary Category:
Radiation Oncology, Treatment Protocols
(CODEL) Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Eligible for screening study DCP 001
NCT#00887146
(Click for More Info)
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG BN003
Primary Category:
Radiation Oncology, Treatment Protocols
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Eligible for screening study DCP 001
NCT#03180268
(Click for More Info)
NRG BN007
Primary Category:
Radiation Oncology, Treatment Protocols
Status:
Temporarily Closed
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
(Click for More Info)
NCT#04396860
BN007 is temporarily closed to accrual effective April 27, 2022 at 5pm ET.
NRG BN010
Primary Category:
Radiation Oncology, Treatment Protocols
Status:
Temporarily Closed
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
(Click for More Info)
NCT#04729959
BN010 is temporarily closed to accrual, effective January 30, 2023.
NRG BN012
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Brain, Brain Metastatic
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
(Click for More Info)
NCT#05438212
NRG CC003
Primary Category:
Radiation Oncology
Disease Category:
Brain, Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage
Randomized Phase II/III Trial of Prophylatic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
NCT#02635009
(Click for More Info)
Eligible for screening study DCP 001
CC003 is closed to accrual, effective June 21, 2022 at 5pm ET
Protocol Schema AE Flowsheet
NRG CC009
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Brain, Lung, Lung - Small Cell
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Eligible for screening study DCP 001
(Click for More Info)
NCT#04804644
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Breast
AFT-25 COMET
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Breast, Breast DCIS
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
NCT#02926911
(Click for More Info)
AFT-25 COMET is closed to accrual, effective January 13, 2023.
Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, Kootenai Health, & Saint Alphonsus Regional Medical Center.
Sites must submit to MCC a protocol specific Training Log and an AFT Delegation of Authority Log before any patient registrations may take place.
Email aboerner@mtcancer.org for additional QOLs and resources in Spanish.
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A011106
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Eligible for screening study DCP 001
NCT#01953588
(Click for More Info)
Effective today, July 15th, 2019, study A011106 is permanently closed to new patient registration.
ALLIANCE A011202
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
A011202 is is permanently closed to new patient pre-registration (OPEN Step 0) and randomization (OPEN Step 1), effective July 1, 2022.
NCT#01901094
(Click for More Info)
ALLIANCE A011203
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
NCT#02311933
(Click for More Info)
A011203 is permanently closed to accrual effective May 19, 2017.
ALLIANCE A011401
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast, Breast Neoadjuvant
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Eligible for screening study DCP 001
NCT#02750826
(Click for More Info)
A011401 permanently closed to patient randomization (Step 2), effective 03/25/21.
A011401 is permanently closed to new patient accrual (Step 1), effective 02/15/21.
The A011401 Health Behaviors and Patient Reported Outcomes substudy HO1 will soon meet its study accrual goal. Therefore, EFFECTIVE July 06, 2017 at 4:30 pm ET, A011401 substudy HO1 will permanently close to new patient accrual.
ALLIANCE A011502
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
A011502 is permanently closed effective December 4, 2020.
Patients previously enrolled in A011502 patients are eligible for enrollment in companion study A211601 and may be consented with A211601 Retrospective Consent.
Patients enrolling in A011502 patients must be enrolled in companion study A211601 and may be consented with A211601 Consent.
Eligible for screening study DCP 001
NCT#02927249
(Click for More Info)
ALLIANCE A011801
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Eligible for screening study DCP 001
(Click for More Info)
NCT#04457596
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A171601
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
NCT#03633331
(Click for More Info)
Eligible for screening study DCP 001
Effective Tuesday, March 3rd, 2020, at 4:30 PM ET, study A171601 is permanently closed to new patient registration.
ALLIANCE A191901
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Adjuvant Breast, Breast
Status:
Temporarily Closed
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Eligible for screening study DCP 001
(Click for More Info)
NCT#04379570
A191901 is temporarily closed to accrual, effective November 16, 2022.
A191901 is permanently closed to accrual of non-Black women over 50, effective February 25, 2022 at 4:30pm (ET)
A191901 is permanently closed to accrual of non-Black women, effective April 15, 2022 at 4:30pm (ET)
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ALLIANCE A221505
Primary Category:
Radiation Oncology, Surgical Protocols
Disease Category:
Adjuvant Breast, Breast
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
NCT#03414970
(Click for More Info)
Eligible for screening study DCP 001
A221505 is permanently closed to accrual, effective August 11, 2021, at 4:30pm ET.
ALLIANCE A221702
Primary Category:
Surgical Protocols
Disease Category:
Adjuvant Breast, Breast
ARM: Axillary Reverse Mapping – A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping
Eligible for screening study DCP 001
NCT#03927027
(Click for More Info)
A221702 is closed to accrual, effective June 30, 2022, at 4:30pm ET
ALLIANCE A221803
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Adjuvant Breast, Breast
Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial
(Click for More Info)
NCT#04989504
Eligible for screening study DCP 001
A221803 has reached the planned number of participating sites for the trial and are not adding anymore as of 10/03/2022. If you haven’t already received a Site Approval Letter from study, your site will not be able to participate at this time. If additional slots are opened to sites in the future study will let us know.
ALLIANCE A231701CD
Primary Category:
Cancer Care Delivery, Surgical Protocols
Disease Category:
Breast, Cancer Care Delivery
Increasing Socioeconomically Disadvantaged Patients’ Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making Intervention
Eligible for screening study DCP 001
NCT#03766009
A231701CD is permanently closed to new patient registration for the primary objective, effective December 31, 2021 at 4:30pm (ET)
(Click for More Info)
Limited institution study – Only open to: Billings Clinic
ECOG-ACRIN E5103
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
E5103 Step 3 registration, registration to the EL112LAB substudy, is closed to accrual on July 29, 2016.
NCT#00433511
(Click for More Info)
ECOG-ACRIN EA1131
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
Closed to accrual effective 03/30/2021
NCT#02445391
(Click for More Info)
ECOG-ACRIN EA1151
Primary Category:
Cancer Control and Prevention Protocols
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Limited institution study: open only to Saint Alphonsus Health System.
(Click for More Info)
NCT#03233191
Eligible for screening study DCP 001
ECOG-ACRIN EA1181
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
EA1181 HER2+/ER+ Subset with tumor size 2.1-3.0 cm and node negative is closed to accrual, effective July 27, 2022
(Click for More Info)
NCT#04266249
ECOG-ACRIN EA1183
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
(Click for More Info)
NCT#04316117
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
ECOG-ACRIN PACCT-1
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
Ancillary study EL112LAB for the PACCT1 Trial has reached its accrual goal. Therefore, PACCT1 Step 3 registration (EL112LAB) is closed to accrual effective Friday, July 3, 2015 at 5:00 pm EST. (E5103 accrual remains open for EL112LAB.)
NCT#00310180
(Click for More Info)
NRG B-51
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#01872975
(Click for More Info)
NSABP B-51 is permanently closed to accrual on December 28, 2020.
The accrual goal for the Behaviorial and Health Outcomes (BAHO) Quality of Life component in the B-51 trial has been met. Therefore, effective August 6th, 2018, accrual will be closed to the QoL component. The B-51 trial remains open to accrual.
NRG B-55
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast, Breast Neoadjuvant
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#02032823
(Click for More Info)
B-55 is closed to accrual effective April 29, 2019.
Closure of Part 1 and Part 2 Screening will occur on April 1, 2019 at 5:00 PM Eastern Time. Accrual to the NSABP B-55/BIG 6-13 trial will close on April 29, 2019 at 5:00 PM Eastern Time. Patients, who are in screening, must be randomized to the study by 5:00 PM on April 29, 2019.
Protocol Letter to Investigators AE Flowsheet-Physician AE Flowsheet-Nurse Or Coordinator
NRG BR002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Permanently closed to accrual effective May 27, 2022. Phase IIR primary endpoint analysis is complete, and the results do not support reopening accrual to address the phase III research question.
NCT#02364557
(Click for More Info)
NRG BR003
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Eligible for screening study DCP 001
BR003 is closed to accrual effective April 22, 2022, at 5pm ET.
NCT#02488967
(Click for More Info)
NRG BR007
Primary Category:
Radiation Oncology, Treatment Protocols
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
(Click for More Info)
NCT#04852887
Eligible for screening study DCP 001
NRG CCTG MA.39
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Eligible for screening study DCP 001
For CCTG MA.39, please credit NRG all accruals.
CCTG MA.39-Optional Questionnaire Component is closed to accrual effective August 2, 2022
NCT#03488693
(Click for More Info)
SWOG S1007
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
S1007 Circulating Biomarker Assessment for Late Relapse Translational Medicine (CBALR TM Substudy (Step 3)) is activated effective July 27, 2021.
S1007 is permanently closed to accrual for Step 1 registration effective October 1, 2015 at 11:59 p.m. PST. The study is permanently closed to accrual for Step 2 registration effective October 15, 2015 at 11:59 p.m. PST. Patients who will be registered to Step 1 and Step 2 at the same time (patients whose Recurrence Score is already known) must be registered prior to closure of Step 1 registration on October 1, 2015.
NCT#01272037
(Click for More Info)
SWOG S1207
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy
NCT#01674140
(Click for More Info)
S1207 is closed to accrual effective May 1, 2019.
Eligible for screening study DCP 001
SWOG S1416
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, with or Without Brain Metastases
NCT#02595905
(Click for More Info)
Effective, today, June 15th, 2019, SWOG S1416, is permanently closed to accrual.
SWOG S1418
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#02954874
(Click for More Info)
Site Delegation of Tasks Log required prior to registration of any patients.
S1418 Step 1 Registration is permanently closed to accrual effective June 30, 2021, at 12:oo pm Pacific Time.
S1418 Step 2 Registration is permanently closed to accrual effective August 21, 2021, at 11:59 pm Pacific Time.
Effective June 23, 2020, the BAHO substudy for SWOG study S1418/BR006, is permanently closed to accrual.
SWOG S1501
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Eligible for screening study DCP 001
NCT#03418961
(Click for More Info)
S1501, Arm 3 is permanently closed to accrual, effective July 29, 2021, at 11:59pm Pacific Time.
SWOG S1703
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
NCT#03723928
(Click for More Info)
Eligible for screening study DCP 001
SWOG S1706
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
NCT#03598257
(Click for More Info)
SWOG S2007
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
(Click for More Info)
NCT#04647916
SWOG S2013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04871542
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Cancer Care Delivery
ALLIANCE A231701CD
Primary Category:
Cancer Care Delivery, Surgical Protocols
Disease Category:
Breast, Cancer Care Delivery
Increasing Socioeconomically Disadvantaged Patients’ Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making Intervention
Eligible for screening study DCP 001
NCT#03766009
A231701CD is permanently closed to new patient registration for the primary objective, effective December 31, 2021 at 4:30pm (ET)
(Click for More Info)
Limited institution study – Only open to: Billings Clinic
ECOG-ACRIN EAQ162CD
Primary Category:
Cancer Care Delivery, Cancer Control and Prevention Protocols
Disease Category:
Cancer Care Delivery, Colon, Gastrointestinal, Rectal
Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
NCT#03516942
(Click for More Info)
Eligible for screening study DCP 001
EAQ162CD closed to accrual Monday, July 6, 2020.
SWOG S1415CD
Primary Category:
Cancer Care Delivery, Cancer Control and Prevention Protocols
Disease Category:
Cancer Care Delivery
A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -Trial Assessing CSF Prescribing Effectiveness and Risk (TRACER)
Limited site participation. Open only to Billings Clinic, Bozeman Health, and Saint Alphonsus
Effective December 2nd, 2019, study S1415CD is permanently closed to low or high risk accruals. Intermediate risk accrual remains open for randomized sites.
Closed to accrual effective April 15, 2020. Accrual goals met.
NCT#02728596
(Click for More Info)
Eligible for screening study DCP 001
SWOG S1912CD
Primary Category:
Cancer Care Delivery
Disease Category:
Cancer Care Delivery
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Eligible for screening study DCP 001
(Click for More Info)
NCT#04960787
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Gastrointestinal
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A021502
Primary Category:
Treatment Protocols
Disease Category:
Colon, Gastrointestinal
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Eligible for screening study DCP 001
NCT#02912559
(Click for More Info)
Site Delegation of Tasks Log required prior to registration of any patients.
A021502 is closed to accrual, effective January 17, 2023, at 4:30 PM ET.
ALLIANCE A021602
Primary Category:
Treatment Protocols
Disease Category:
Carcinoid, Neuroendocrine, Pancreatic
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
NCT#03375320
(Click for More Info)
Eligible for screening study DCP 001
ALLIANCE A021703
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Eligible for screening study DCP 001
NCT#04094688
(Click for More Info)
A021703 is permanently closed to accrual, effective December 15, 2022.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ALLIANCE A221805
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Colon, Gastrointestinal, Rectal
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Eligible for screening study DCP 001
A221805-Substudy SI1 is closed to accrual, effective September 15, 2022, at 4:30pm ET
(Click for More Info)
NCT#04137107
ALLIANCE C80702
Primary Category:
Treatment Protocols
Disease Category:
Colon, Gastrointestinal
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
CALGB 80702 is permanently closed to new patient accrual effective, November 20. 2015 at 4:30 PM ET.
NCT#01150045
(Click for More Info)
ECOG-ACRIN EA2142
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Neuroendocrine
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
EA21452 is closed to accrual effective April 1, 2021.
(Click for More Info)
NCT#02595424
ECOG-ACRIN EA2165
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Anal, Gastrointestinal
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Study has reached its accrual goal and is closed to accrual effective August 31, 2021.
(Click for More Info)
NCT#03233711
Eligible for screening study DCP 001
ECOG-ACRIN EA2176
Primary Category:
Treatment Protocols
Disease Category:
Anal, Gastrointestinal
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
Eligible for screening study DCP 001
(Click for More Info)
NCT#04444921
ECOG-ACRIN EA2182
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Anal, Gastrointestinal
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
NCT#04166318
(Click for More Info)
ECOG-ACRIN EA2183
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Esophageal, Esophageal Metastatic, Gastrointestinal, Stomach, Stomach Metastatic
A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
NCT#04248452
(Click for More Info)
Eligible for screening study DCP 001
EA2183 is reopened to accrual with the implementation of Amendment 2, effective April 5, 2022
ECOG-ACRIN EA2186
Primary Category:
Surgical Protocols, Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic Metastatic
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
(Click for More Info)
NCT#04233866
ECOG-ACRIN EA2187
Primary Category:
Treatment Protocols
Disease Category:
Cholangiocarcinoma, Gastrointestinal
Status:
Temporarily Closed
A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
(Click for More Info)
NCT#04175912
EA2187 is temporarily closed to patient accrual effective March 31, 2021.
ECOG-ACRIN EA2201
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Rectal
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
(Click for More Info)
NCT#04751370
ECOG-ACRIN EAQ162CD
Primary Category:
Cancer Care Delivery, Cancer Control and Prevention Protocols
Disease Category:
Cancer Care Delivery, Colon, Gastrointestinal, Rectal
Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
NCT#03516942
(Click for More Info)
Eligible for screening study DCP 001
EAQ162CD closed to accrual Monday, July 6, 2020.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG GI002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Rectal
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
NCT#02921256
(Click for More Info)
GI002 is permanently closed to accrual effective February 22, 2021. Sites need to continue to collect long-term follow-up data on enrolled patients.
NRG GI004
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Eligible for screening study DCP 001
NRG GI004 reopened to accrual effective January, 29, 2021.
NCT#02997228
(Click for More Info)
Site Delegation of Tasks Log required prior to registration of any patients.
NRG GI005
Primary Category:
Treatment Protocols
Disease Category:
Colon, Gastrointestinal
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
NCT#04068103
(Click for More Info)
GI005 is reopened upon implementation of Amendment 1, effective June 15, 2021.
NRG GI008
Primary Category:
Treatment Protocols
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
(Click for More Info)
NCT#05174169
NRG R0848
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic
A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
NCT#01013649
(Click for More Info)
Eligible for screening study DCP 001
R0848 closed to accrual at 5 PM ET Friday, June 1, 2018, because it reached its accrual target. Step 2 randomization will remain open. All patients registered to Step 1 by Friday, June 1, 2018 will proceed to the randomization step (Step 2). If patients are unable to be randomized, Step 2 will still be completed with the reason for no randomization being provided.
NRG R1010
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Esophageal, Gastrointestinal
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
R1010 is closed to STEP 1 registration at 5 PM EST on Tuesday, November 10, 2015, because the study has reached its accrual target. STEP 2 registration will remain open and all eligible patients determined to be HER2 positive will be permitted to be randomized for treatment on this trial.
NCT#01196390
(Click for More Info)
SWOG S1513
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic, Pancreatic Metastatic
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
NCT#02890355
(Click for More Info)
S1513 is permanently closed to accrual effective immediately. 12/13/17. At a planned interim analysis, our Data and Safety Monitoring Committee recommended that S1513 be closed permanently based on the results. These results will be shared, and further instructions given in a forthcoming letter to patients and investigators. Patients currently receiving ABT-888 (Veliparib) must discontinue the experimental treatment but may continue on FOLFIRI alone. Patients on both arms should continue study follow-up.
SWOG S1613
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
S1613, Step 2 (randomization) is permanently closed to accrual, effective March 31, 2022.
S1613 is permanently closed to accrual, effective December 31, 2021.
NCT#03365882
(Click for More Info)
SWOG S1815
Primary Category:
Treatment Protocols
Disease Category:
Cholangiocarcinoma, Gallbladder, Gastrointestinal
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Eligible for screening study DCP 001
NCT#03768414
(Click for More Info)
S1815 is permanently closed to accrual effective February 15, 2021, at 11:59pm Pacific.
SWOG S1922
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Small Bowel
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
NCT#04205968
(Click for More Info)
SWOG S2001
Primary Category:
Treatment Protocols
Disease Category:
Pancreatic, Pancreatic Metastatic
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
(Click for More Info)
NCT#04548752
SWOG S2013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04871542
SWOG S2107
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Rectal, Rectal Metastatic
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
(Click for More Info)
NCT#05308446
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Genitourinary
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A031201
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
Phase III Trial of Enzalutamide (NSC #766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
A031201 is permanently closed to new patient accrual, effective August 31, 2016.
NCT#01949337
(Click for More Info)
ALLIANCE A031501
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
NCT#03244384
(Click for More Info)
Eligible for screening study DCP 001
A031501 is permanently closed to new accrual, effective August 24, 2021.
Protocol Schema AE Flowsheet
ALLIANCE A031701
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
NCT#03609216
(Click for More Info)
ALLIANCE A031702
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary, Prostate, Renal
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
(Click for More Info)
NCT#03866382
ALLIANCE A031704
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal, Renal Metastatic
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
(Click for More Info)
Eligible for screening study DCP 001
NCT#03793166
A031704 is reactivated to new patient registration (Step 1), effective March 26, 2021.
ALLIANCE A031801
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Renal, Renal Metastatic
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)
NCT#04071223
(Click for More Info)
ALLIANCE A031803
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
NCT#04164082
(Click for More Info)
Effective 09/30/20, new patient registration (Step 1) of A031803 is reopened to accrual.
ALLIANCE A031902
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate Metastatic
CASPAR – A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Eligible for screening study DCP 001
A031902 is reactivated to new patient enrollment, effective July 27, 2021.
(Click for More Info)
NCT#04455750
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ALLIANCE C90203
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
CALGB 90203 is permanently closed to new patient accrual effective Friday, October 2, 2015 at 4:30 PM EST.
NCT#00430183
(Click for More Info)
ECOG-ACRIN EA8143
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Eligible for screening study DCP 001
NCT#03055013
(Click for More Info)
EA8143 is closed to new patient accrual effective June 2, 2021.
Quality of Life (QOL) component reached its accrual goal. Therefore, QOL is closed to new patient accrual effective June 19, 2020.
Site Delegation of Tasks Log required prior to registration of any patients.
ECOG-ACRIN EA8153
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
NCT#03419234
(Click for More Info)
EA8153 closed to accrual effective April 2, 2021.
ECOG-ACRIN EA8171
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
NCT#03697148
(Click for More Info)
ECOG-ACRIN EA8183
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Eligible for screening study DCP 001
(Click for More Info)
NCT#04484818
ECOG-ACRIN EA8185
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Bladder, Genitourinary
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
(Click for More Info)
NCT#04216290
ECOG-ACRIN EA8191
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate
Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Eligible for screening study DCP 001
(Click for More Info)
NCT#04423211
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG GU002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
NCT#03070886
(Click for More Info)
GU002 is closed to accrual, effective September 6, 2022.
NRG GU003
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Eligible for screening study DCP 001
NCT#03274687
(Click for More Info)
GU003 is closed to accrual effective July 9, 2018, because it has reached its accrual target. All patients registered to Step 1 registration by Monday, July 9, 2018 will be permitted to proceed to the randomization step (Step 2).
NRG GU005
Primary Category:
Radiation Oncology
Disease Category:
Genitourinary, Prostate
Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Eligible for screening study DCP 001
NCT#03367702
(Click for More Info)
GU005 is closed to accrual effective June 8, 2022 at 5pm ET.
RT Credentialing Required
Because the AJCC staging version 8 was not ready for the study activation, AJCC staging version 7 must be used.
NRG GU006
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Recurrent
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
NCT#03371719
NRG-GU006 permanently closed to accrual, effective May 19, 2020, because it has reached its accrual target.
(Click for More Info)
NRG GU007
Primary Category:
Radiation Oncology
Disease Category:
Genitourinary, Prostate
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (with Initial Phase I)
NCT#04037254
GU007 is reopened to accrual to phase I/dose level 3, effective September 26, 2022.
GU007 Phase II is not open to accrual as of January 27, 2022.
(Click for More Info)
NRG GU008
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
(Click for More Info)
NCT#04134260
Eligible for screening study DCP 001
GU008 is reopened to accrual upon implementation of Amendment 2, effective December 7, 2021.
NRG GU009
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Prostate
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Eligible for screening study DCP 001
Optional Imaging Sub Study is temporarily closed accrual, effective December 21, 2021
(Click for More Info)
NCT#04513717
NRG GU010
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Prostate
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
(Click for More Info)
NCT#05050084
NRG R0534
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Recurrent
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
NCT#00567580
(Click for More Info)
R0534 closed to accrual at 5 PM EST Monday, March 30, 2015, because it reached its accrual target.
NRG R0815
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
R0815 closed to accrual at 5 PM EST on Monday, March 7, 2016, because the study has reached its accrual target.
NCT#00936390
(Click for More Info)
Protocol
NRG R0924
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Effective today, June 24th, 2019, study RTOG 0924 has reached its accrual goal and is now closed.
(QOL Sub-study is closed as its accrual goal has been met.)
Eligible for screening study DCP 001
NCT#01368588
(Click for More Info)
SWOG S0931
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
S0931 has met its accrual goal and is permanently closed to accrual effective September 15, 2016 at 11:59 p.m. Pacific Time.
NCT#01120249
(Click for More Info)
SWOG S1216
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
NCT#01809691
(Click for More Info)
S1216 has met its accrual goal and is permanently closed to accrual effective July 15, 2017 at 11:59 p.m. Pacific.
SWOG S1314
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
NCT#02177695
(Click for More Info)
S1314 has met its accrual goal and is permanently closed to accrual effective December 1, 2017 at 11:59 p.m. Pacific.
SWOG S1500
Primary Category:
Treatment Protocols
Disease Category:
Renal, Renal Metastatic
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
NCT#02761057
(Click for More Info)
Effective December 15th, 2019, study S1500 is permanently closed to accrual.
SWOG S1602
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer
NCT#03091660
(Click for More Info)
Eligible for screening study DCP 001
S1602 will permanently close to accrual effective December 15, 2020.
SWOG S1802
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
NCT#03678025
(Click for More Info)
Eligible for screening study DCP 001
SWOG S1806
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Bladder, Genitourinary
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
(Click for More Info)
NCT#03775265
Eligible for screening study DCP 001
SWOG S1937
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary
A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Eligible for screening study DCP 001
(Click for More Info)
NCT#04579224
SWOG S2013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04871542
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Gynecologic
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
GOG Foundation GOG-3015 / Y039523
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian, Ovarian Metastatic
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT#03038100
(Click for More Info)
Limited institution study: Open ONLY to Billings Clinic, Bozeman Deaconess Cancer Center & Community Medical Center – Missoula
GOG Foundation GOG-3024/GCT1015-05
Primary Category:
Treatment Protocols
Disease Category:
Cervical, Cervical Metastatic, Gynecologic
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
NCT#03786081
(Click for More Info)
NRG CC008
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Ovarian
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Eligible for screening study DCP 001
(Click for More Info)
NCT#04251052
NRG G0274
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Gynecologic
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Eligible for screening study DCP 001
NCT#01414608
(Click for More Info)
Please be aware that as of the 1st June 2017, sites are no longer permitted to screen for or provide informed consent forms for potential OUTBACK/GOG274/RTOG1174 patients as the protocol has reached its accrual goal.
NRG GY004
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum sensitive ovarian, fallopian tube, or primary peritoneal cancer
NCT#02446600
(Click for More Info)
Closed to accrual effective November 10, 2017. Accrual goal met.
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
NRG GY005
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
NCT#02502266
(Click for More Info)
Eligible for screening study DCP 001
GY005 closed to accrual in US, Canada and South Korea effective October 2, 2020.
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
NRG GY012
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, Gynecologic
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer
NCT#03660826
(Click for More Info)
GY012 is reopened to accrual, effective May 23, 2022.
NRG GY014
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Gynecologic, Ovarian
A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
(Click for More Info)
NCT#03348631
NRG GY016
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
NCT#03602586
(Click for More Info)
GY016 is permanently closed to accrual and will not advance to second stage accrual, effective February 1, 2021.
NRG GY018
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Gynecologic
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVB or Recurrent Endometrial Cancer
Eligible for screening study DCP 001
GY018 is closed to accrual, effective December 6, 2022.
(Click for More Info)
NCT#03914612
NRG GY019
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian, Ovarian Metastatic
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Eligible for screening study DCP 001
(Click for More Info)
NCT#04095364
NRG GY020
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Endometrial, Gynecologic
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Eligible for screening study DCP 001
GY020 is closed to accrual, effective August 29, 2022
(Click for More Info)
NCT#04214067
NRG GY023
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
(Click for More Info)
NCT#04739800
GY023 is nearing accrual goal and is anticipated to close to accrual, effective March 1, 2023.
NRG GY024
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
GYN Other, Gynecologic
Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial
(Click for More Info)
NCT#05076942
NRG GY026
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, Gynecologic
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
(Click for More Info)
NCT#05256225
SWOG S2013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04871542
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Head and Neck
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ECOG-ACRIN EA3132
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
NCT#02734537
(Click for More Info)
ECOG-ACRIN EA3161
Primary Category:
Treatment Protocols
Disease Category:
Head and Neck
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
NCT#03811015
(Click for More Info)
ECOG-ACRIN EA3163
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Head and Neck
Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a (and selected T4b) nasal and paranasal sinus squamous cell carcinoma (NPNSCC)
NCT#03493425
(Click for More Info)
Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21
ECOG-ACRIN EA3191
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
(Click for More Info)
NCT#04671667
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG HN002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
NCT#02254278
(Click for More Info)
Closed effective February 7, 2017. Accrual goal met.
NRG HN004
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
NCT#03258554
(Click for More Info)
Site Delegation of Tasks Log required prior to registration of any patients.
HN004 is permanently closed to accrual effective September 1, 2022.
NRG HN005
Primary Category:
Radiation Oncology
Disease Category:
Head and Neck
A Randomized Phase II/II Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Open to Phase II enrollment
(Click for More Info)
NCT#03952585
NRG R1216
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
(Click for More Info)
NCT#01810913
SWOG S2013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04871542
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Leukemia
ALLIANCE A041202
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study Of Bendamustine PLUS Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone In Untreated Older Patients (≥ 65 Years Of Age) With Chronic Lymphocytic Leukemia (CLL)
A041202 is permanently closed to accrual May 16, 2016 at 4:30 pm ET.
NCT#01886872
(Click for More Info)
ALLIANCE A041501
Primary Category:
Treatment Protocols
Disease Category:
Acute Lymphocytic Leukemia, Leukemia
Status:
Temporarily Closed
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
NCT#03150693
(Click for More Info)
Eligible for screening study DCP 001
Temporary suspension effective May 24, 2022 due to Alliance DSMB review.
Confirmation of Tolerability Phase and slot reservation completed and study currently open to Phase III enrollment as of 06/12/2018. See Section 4.4 for registration and randomization instructions.
ALLIANCE A041701
Primary Category:
Treatment Protocols
Disease Category:
Acute Myeloid Leukemia, Leukemia
Status:
Temporarily Closed
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
NCT#03701308
(Click for More Info)
A041701, pre-registration (Step 0) is temporarily closed to accrual, effective November 19, 2021 at 4:30 PM ET.
ALLIANCE A041702
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
NCT#03737981
(Click for More Info)
Eligible for screening study DCP 001
A041702 is closed to accrual, effective July 15, 2022
A041702, Step 1 registration, is closed to accrual, effective November 1, 2022
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ALLIANCE A231602CD
Primary Category:
Cancer Care Delivery
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia, Multiple Myeloma
Assessing Financial Difficulty in Patients with Blood Cancers
NCT#03870633
(Click for More Info)
Eligible for screening study DCP 001
A231602CD is permanently closed to accrual effective February 1, 2021.
Limited site participation. Open only to Benefis Sletten Cancer Institute, Billings Clinic, Community Hospital of Anaconda, Community Medical Center, and Saint Alphonsus Regional Medical Center
ECOG-ACRIN E1910
Primary Category:
Treatment Protocols
Disease Category:
Acute Lymphocytic Leukemia, Leukemia
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Eligible for screening study DCP 001
NCT#02003222
(Click for More Info)
E1910 is closed to accrual effective October 15, 2019.
ECOG-ACRIN E1912
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
E1912 closed to accrual June 9, 2016 at 5:00 pm ET due to reaching its accrual goal.
NCT#02048813
(Click for More Info)
ECOG-ACRIN EA9161
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
NCT#03701282
(Click for More Info)
Eligible for screening study DCP 001
EA9161 is closed to new accrual effective April 30, 2021.
EA9161 Quality of Life (QOL) component has reach accrual goal. Therefore, EFFECTIVE August 5, 2020, the QOL component is closed to new accrual.
ECOG-ACRIN EA9171
Primary Category:
Treatment Protocols
Disease Category:
Chronic Myeloid Leukemia, Leukemia
BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD
NCT#03516279
(Click for More Info)
ECOG-ACRIN NHLBI-MDS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Leukemia, Myelodysplastic Syndrome
The National Myelodysplastic Syndromes (MDS) Study
NCT#02775383
(Click for More Info)
Eligible for screening study DCP 001
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
Suspension to enrollment of new participants and follow-up research sample collection and shipment is lifted effective May 18, 2020, for NHLBI-MDS. Refer to memo dated March 27, 2020, on conducting remote follow-up data for enrolled participants.
SWOG S1203
Primary Category:
Treatment Protocols
Disease Category:
Acute Myeloid Leukemia, Leukemia
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) Versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
S1203 is permanently closed to accrual effective November 15, 2015.
NCT#01802333
(Click for More Info)
SWOG S1612
Primary Category:
Treatment Protocols
Disease Category:
Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome
A Randomized Phase II/III Trial of “Novel Therapeutics” versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older
NCT#03092674
(Click for More Info)
Effective 09/01/20, S1612 is permanently closed to accrual.
Effective immediately,10/25/18, and until further notice, patients will no longer receive nivolumab as part of this study. Additional details are provided in the Investigator Letter and Patient Information Letter.
SWOG S1712
Primary Category:
Treatment Protocols
Disease Category:
Chronic Myeloid Leukemia, Leukemia
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
NCT#03654768
(Click for More Info)
S1712 is permanently closed to accrual, effective October 20, 2022.
SWOG S1925
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Lymphoma
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04269902
Lung
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A081801
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
(See required screening study ALLIANCE A151216)
(Click for More Info)
NCT#04267848
ALLIANCE A151216
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A screening trial for A081105 (closed), A081801, E4512, and EA5142 (closed).
Eligible for screening study DCP 001
Effective, August 26, 2019, enrollment is temporarily suspended for patients with squamous histology.
NCT#02194738
(Click for More Info)
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A171901
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist’s/Patient’s Choice)
Eligible for screening study DCP 001
(Click for More Info)
NCT#04533451
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ALLIANCE A221504
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)
NCT#03087708
(Click for More Info)
Eligible for screening study DCP 001
A221504 is unlikely to meet accrual goal. Therefore, it is permanently closed to accrual effective June 30, 2020.
ALLIANCE C140503
Primary Category:
Surgical Protocols
Disease Category:
Lung, Lung - Non-Small Cell
A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm)
Peripheral Non-Small Cell Lung Cancer
(See Section 9.0 for required surgical credentialing.)
NCT#00499330
(Click for More Info)
C140503 is permanently closed to accrual effective March 13, 2017 at 4:30 pm EDT.
ALLIANCE C30610
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Limited Stage
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Eligible for screening study DCP 001
NCT#00632853
(Click for More Info)
Effective December 1st, 2019, study CALGB 30610 is permanently closed to new patient accrual.
ECOG-ACRIN E4512
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
NCT#02201992
(Click for More Info)
ECOG-ACRIN EA5142
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
NCT#02595944
(Click for More Info)
Effective today, October 1st, 2019, study EA5142 has met accrual goals and is permanently closed to accrual.
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
ECOG-ACRIN EA5161
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
NCT#03382561
(Click for More Info)
EA5161 is closed to accrual effective December 7, 2018 at 5:00 PM ET.
ECOG-ACRIN EA5162
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
NCT#03191149
(Click for More Info)
EA5162 is reopened to accrual, effective December 20, 2022.
ECOG-ACRIN EA5163
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
NCT#03793179
Eligible for screening study DCP 001
(Click for More Info)
ECOG-ACRIN EA5181
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Eligible for screening study DCP 001
(Click for More Info)
NCT#04092283
ECOG-ACRIN EA5182
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Eligible for screening study DCP 001
(Click for More Info)
NCT#04181060
ECOG-ACRIN EA5191
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell Metastatic
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
(Click for More Info)
NCT#04310007
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
NRG CC003
Primary Category:
Radiation Oncology
Disease Category:
Brain, Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage
Randomized Phase II/III Trial of Prophylatic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
NCT#02635009
(Click for More Info)
Eligible for screening study DCP 001
CC003 is closed to accrual, effective June 21, 2022 at 5pm ET
Protocol Schema AE Flowsheet
NRG CC009
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Brain, Lung, Lung - Small Cell
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Eligible for screening study DCP 001
(Click for More Info)
NCT#04804644
NRG LU001
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC
LU001 is closed effective December 15, 2016 because it has reached its accrual target.
NCT#02186847
(Click for More Info)
NRG LU002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Temporarily Closed
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
NCT#03137771
(Click for More Info)
LU002 is temporarily closed to accrual, effective November 12, 2021.
NRG LU004
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined with MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
NCT#03801902
(Click for More Info)
LU004 is permanently closed to accrual effective June 21, 2021.
NRG LU005
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Limited Stage
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Site staff must complete Rave ePro online training prior to the first patient enrollment.
LU005 is closed to accrual for US sites on June 23, 2022 at 5pm ET.
NCT#03811002
(Click for More Info)
NRG LU007
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
(Click for More Info)
NCT#04402788
SWOG LUNGMAP
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
NCT#03851445
(Click for More Info)
Eligible for screening study DCP 001
Effective, June 30th, 2019, the sub-study S1400GEN is closed to accrual.
SWOG S1400
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
Eligible for screening study DCP 001
NCT#02154490
(Click for More Info)
Closure to accrual for S1400 is effective January 28, 2019.
SWOG S1400A
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of MEDI4736 for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
Permanent Closure of S1400A, Arm 2-Docetaxel due to FDA approval of nivolumab. Permanent closure of sub-study due to a revised trial design.
NCT#02154490
(Click for More Info)
SWOG S1400B
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
S1400B is closed to accrual effective December 12, 2016, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490
(Click for More Info)
SWOG S1400C
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
Permanent closure of Arm 2 ONLY due to a revised trial design.
S1400C is permanently closed to accrual, effective September 1, 2016, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490
(Click for More Info)
SWOG S1400I
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)
Eligible for screening study DCP 001
(See required screening study SWOG S1400)
NCT#02785952
(Click for More Info)
S1400I is permanently closed to accrual effective immediately, April 23, 2018. At a planned interim analysis, SWOG’s Data and Safety Monitoring Committee recommended that sub study S1400I be permanently closed to accrual based on the results. This information will be shared and further instructions given in a forthcoming letter to patients and investigators. Patients currently receiving the experimental combination nivolumab plus ipilimumab may continue to receive treatment if the patient is deriving clinical benefit, the patient agrees to continue treatment, and if their physician feels that it is in the best interest of the patient to continue the treatment as an appropriate medical intervention at this time. Patients on both arms should continue study follow-up.
SWOG S1403
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Randomized Phase II Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)(BI 1200.124)
NCT#02438722
(Click for More Info)
S1403 is permanently closed to accrual effective immediately, April 23, 2018.
SWOG S1507
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
NCT#02642042
(Click for More Info)
S1507 has met its accrual goal and will permanently close to accrual effective March 15, 2018 at 11:59 p.m. Pacific.
SWOG S1800A
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
NCT#03971474
(Click for More Info)
S1800A is permanently closed to accrual effective November 16, 2020.
SWOG S1800D
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell Metastatic
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
See Screening Protocol LUNGMAP
(Click for More Info)
NCT#05096663
SWOG S1827
Primary Category:
Radiation Oncology
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Eligible for screening study DCP 001
NCT#04155034
(Click for More Info)
SWOG S1900A
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
NCT#03845296
(Click for More Info)
See Screening Protocol LUNGMAP
S1900A is permanently closed to new accrual effective, February 1, 2021.
Cohort 2 (patients with non-squamous cell lung cancer) is permanently closed to accrual effective February 1. 2021.
Cohort 1 (patients with squamous cell lung cancer) permanently closed to accrual effective November 15, 2020.
SWOG S1900C
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
NCT#04173507
(Click for More Info)
S1900C is permanently closed to accrual effective December 18, 2020.
SWOG S1900E
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
See Screening Protocol LUNGMAP
S1900E reopened to accrual effective May 26, 2021.
(Click for More Info)
NCT#04625647
SWOG S1900F
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell Metastatic
A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)
See Screening Protocol LUNGMAP
(Click for More Info)
NCT#05364645
SWOG S1914
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Eligible for screening study DCP 001
(Click for More Info)
NCT#04214262
SWOG S1929
Primary Category:
Treatment Protocols
Disease Category:
Lung - Small Cell Extensive Stage
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
S1929 is permanently closed to accrual on December 15, 2022, at 12pm Pacific Time.
(Click for More Info)
NCT#04334941
SWOG S1933
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung - Non-Small Cell
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
(Click for More Info)
NCT#04310020
SWOG S1934
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
(Click for More Info)
NCT#04989283
S1934 is reopened to accrual upon implementation of Revision 1, effective March 1, 2022.
SWOG S2013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04871542
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Lymphoma
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A021602
Primary Category:
Treatment Protocols
Disease Category:
Carcinoid, Neuroendocrine, Pancreatic
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
NCT#03375320
(Click for More Info)
Eligible for screening study DCP 001
ALLIANCE A051701
Primary Category:
Treatment Protocols
Disease Category:
Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Status:
Temporarily Closed
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
NCT#03984448
(Click for More Info)
A051701 is temporarily closed to accrual effective August 2, 2021.
A051701 accrual of patients with double expressing lymphoma (DEL) is temporarily halted effective August 2, 2021.
A051701 accrual of patients of all ages with double hit lymphoma (DHL) is temporarily halted effective September 28, 2020.
ALLIANCE A051902
Primary Category:
Treatment Protocols
Disease Category:
Lymphoma, Non-Hodgkin Lymphoma
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
(Click for More Info)
NCT#04803201
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ECOG-ACRIN E4412
Primary Category:
Treatment Protocols
Disease Category:
Hodgkin Lymphoma, Lymphoma
A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
NCT#01896999
(Click for More Info)
E4412 is permanently closed to accrual effective June 15, 2021.
ECOG-ACRIN EA4151
Primary Category:
Treatment Protocols
Disease Category:
Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
NCT#03267433
(Click for More Info)
Eligible for screening study DCP 001
Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21
ECOG-ACRIN EA4181
Primary Category:
Treatment Protocols
Disease Category:
Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma
NCT#04115631
(Click for More Info)
EA4181 is reopened to accrual upon implementation of Addendum 4, effective January 3, 2022.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
SWOG S1608
Primary Category:
Treatment Protocols
Disease Category:
Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Status:
Temporarily Closed
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
S1608 is temporarily closed to accrual, effective February 9, 2022 at 1:00pm Pacific Time
NCT#03269669
(Click for More Info)
SWOG S1826
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Hodgkin Lymphoma, Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
NCT#03907488
Eligible for screening study DCP 001
(Click for More Info)
SWOG S1925
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Lymphoma
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04269902
SWOG S2013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04871542
Molecular Profiling
ALLIANCE A071701
Primary Category:
Treatment Protocols
Disease Category:
Brain, Brain Metastatic, Molecular Profiling
Genomically-Guided Treatment Trial in Brain Metastases
(Click for More Info)
ALLIANCE A151216
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A screening trial for A081105 (closed), A081801, E4512, and EA5142 (closed).
Eligible for screening study DCP 001
Effective, August 26, 2019, enrollment is temporarily suspended for patients with squamous histology.
NCT#02194738
(Click for More Info)
ECOG-ACRIN E4512
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
NCT#02201992
(Click for More Info)
ECOG-ACRIN EA5142
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
NCT#02595944
(Click for More Info)
Effective today, October 1st, 2019, study EA5142 has met accrual goals and is permanently closed to accrual.
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
ECOG-ACRIN EAY131-H
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)
(See required screening study ECOG-ACRIN EAY131)
EAY131-H is closed to accrual, effective December 30, 2022.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-J
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Temporarily Closed
MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
(See required screening study ECOG-ACRIN EAY131)
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
Effective June 14, 2019, sub-study EAY131-J is temporarily closed to accrual.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-K2
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Temporarily Closed
MATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
Effective today, July 18th, 2019, Subprotocol K2: Phase 2 is suspended due to the completion of accrual.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-M
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Temporarily Closed
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
(See required screening study ECOG-ACRIN EAY131)
EAY131 Subprotocol M is temporarily closed to accrual, effective August 3, 2021
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-Z1C
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
(See required screening study ECOG-ACRIN EAY131)
EAY131 (MATCH) Subprotocol Z1C, is closed to accrual effective May 25, 2021.
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-Z1K
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling, Other
Molecular Analysis for Therapy Choice – Phase 2 Study of the Selective ATP-Competitive Inhibitor Ipatasertib (GDC-0068) in Patients with Tumors with AKT Mutation
(See required screening study ECOG-ACRIN EAY131)
Subprotocol EAY131-Z1K has reached its accrual goal and is, therefor permanently closed to accrual effective 11/13/20
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
ECOG-ACRIN EAY131-Z1M
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Temporarily Closed
Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy
(See required screening study ECOG-ACRIN EAY131)
Accrual to EAY131-Z1M is suspended, effective January 17,2023.
(Click for More Info)
NCT#02465060
SWOG S1400
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
Eligible for screening study DCP 001
NCT#02154490
(Click for More Info)
Closure to accrual for S1400 is effective January 28, 2019.
SWOG S1400A
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of MEDI4736 for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
Permanent Closure of S1400A, Arm 2-Docetaxel due to FDA approval of nivolumab. Permanent closure of sub-study due to a revised trial design.
NCT#02154490
(Click for More Info)
SWOG S1400B
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
S1400B is closed to accrual effective December 12, 2016, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490
(Click for More Info)
SWOG S1400C
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
(See required screening study SWOG S1400)
Permanent closure of Arm 2 ONLY due to a revised trial design.
S1400C is permanently closed to accrual, effective September 1, 2016, as the study did not meet the criterion for the interim futility analysis.
NCT#02154490
(Click for More Info)
SWOG S1400I
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)
Eligible for screening study DCP 001
(See required screening study SWOG S1400)
NCT#02785952
(Click for More Info)
S1400I is permanently closed to accrual effective immediately, April 23, 2018. At a planned interim analysis, SWOG’s Data and Safety Monitoring Committee recommended that sub study S1400I be permanently closed to accrual based on the results. This information will be shared and further instructions given in a forthcoming letter to patients and investigators. Patients currently receiving the experimental combination nivolumab plus ipilimumab may continue to receive treatment if the patient is deriving clinical benefit, the patient agrees to continue treatment, and if their physician feels that it is in the best interest of the patient to continue the treatment as an appropriate medical intervention at this time. Patients on both arms should continue study follow-up.
SWOG S1609
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
NCT#02834013
(Click for More Info)
Eligible for screening study DCP 001
Please see http://www.swogstat.org/accrual/dart.htm for up-to-date accrual information and current cohort accrual status (i.e. open, closed, suspended). The website is updated with the most current information daily.
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Multiple Myeloma
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A011203
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
NCT#02311933
(Click for More Info)
A011203 is permanently closed to accrual effective May 19, 2017.
ALLIANCE A061402
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Multiple Myeloma, Other
Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
Eligible for screening study DCP 001
NCT#02516423
(Click for More Info)
Alliance A061402 is permanently closed to new patient registration (Step 1) effective August 15, 2019.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A171601
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
NCT#03633331
(Click for More Info)
Eligible for screening study DCP 001
Effective Tuesday, March 3rd, 2020, at 4:30 PM ET, study A171601 is permanently closed to new patient registration.
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ALLIANCE A231602CD
Primary Category:
Cancer Care Delivery
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia, Multiple Myeloma
Assessing Financial Difficulty in Patients with Blood Cancers
NCT#03870633
(Click for More Info)
Eligible for screening study DCP 001
A231602CD is permanently closed to accrual effective February 1, 2021.
Limited site participation. Open only to Benefis Sletten Cancer Institute, Billings Clinic, Community Hospital of Anaconda, Community Medical Center, and Saint Alphonsus Regional Medical Center
ECOG-ACRIN E1A11
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Eligible for screening study DCP 001
NCT#01863550
(Click for More Info)
E1A11 is closed to accrual, January 29, 2019 at 5:00pm ET.
ECOG-ACRIN E3A06
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
NCT#01169337
(Click for More Info)
E3A06 is closed to accrual effective July 14, 2017 at 5:00pm ET.
ECOG-ACRIN EA1183
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
(Click for More Info)
NCT#04316117
ECOG-ACRIN EAA173
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Eligible for screening study DCP 001
(Click for More Info)
NCT#03937635
ECOG-ACRIN EAA181
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Eligible for screening study DCP 001
(Click for More Info)
NCT#04566328
NRG BR002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Permanently closed to accrual effective May 27, 2022. Phase IIR primary endpoint analysis is complete, and the results do not support reopening accrual to address the phase III research question.
NCT#02364557
(Click for More Info)
SWOG S1416
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, with or Without Brain Metastases
NCT#02595905
(Click for More Info)
Effective, today, June 15th, 2019, SWOG S1416, is permanently closed to accrual.
SWOG S1501
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Eligible for screening study DCP 001
NCT#03418961
(Click for More Info)
S1501, Arm 3 is permanently closed to accrual, effective July 29, 2021, at 11:59pm Pacific Time.
SWOG S1703
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
NCT#03723928
(Click for More Info)
Eligible for screening study DCP 001
SWOG S1803
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Eligible for screening study DCP 001
Occupational Report & Pregnancy Report consent forms available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consents and for any questions.
(Click for More Info)
NCT#04071457
SWOG S2007
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
(Click for More Info)
NCT#04647916
SWOG S2013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04871542
Neuroendocrine
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A021602
Primary Category:
Treatment Protocols
Disease Category:
Carcinoid, Neuroendocrine, Pancreatic
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
NCT#03375320
(Click for More Info)
Eligible for screening study DCP 001
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ECOG-ACRIN EA2142
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Neuroendocrine
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
EA21452 is closed to accrual effective April 1, 2021.
(Click for More Info)
NCT#02595424
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Other
ALLIANCE A011106
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Eligible for screening study DCP 001
NCT#01953588
(Click for More Info)
Effective today, July 15th, 2019, study A011106 is permanently closed to new patient registration.
ALLIANCE A011401
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast, Breast Neoadjuvant
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Eligible for screening study DCP 001
NCT#02750826
(Click for More Info)
A011401 permanently closed to patient randomization (Step 2), effective 03/25/21.
A011401 is permanently closed to new patient accrual (Step 1), effective 02/15/21.
The A011401 Health Behaviors and Patient Reported Outcomes substudy HO1 will soon meet its study accrual goal. Therefore, EFFECTIVE July 06, 2017 at 4:30 pm ET, A011401 substudy HO1 will permanently close to new patient accrual.
ALLIANCE A032002
Primary Category:
Radiation Oncology, Treatment Protocols
Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
(Click for More Info)
NCT#04936230
ALLIANCE A061402
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Multiple Myeloma, Other
Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
Eligible for screening study DCP 001
NCT#02516423
(Click for More Info)
Alliance A061402 is permanently closed to new patient registration (Step 1) effective August 15, 2019.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A221602
Primary Category:
Cancer Control and Prevention Protocols
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
NCT#03578081
(Click for More Info)
Eligible for screening study DCP 001
A221602 is permanently closed to accrual, effective July 26, 2021.
DCP 001
Primary Category:
Cancer Control and Prevention Protocols
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
ECOG-ACRIN EA1181
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
EA1181 HER2+/ER+ Subset with tumor size 2.1-3.0 cm and node negative is closed to accrual, effective July 27, 2022
(Click for More Info)
NCT#04266249
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
ECOG-ACRIN EAY131-Z1K
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling, Other
Molecular Analysis for Therapy Choice – Phase 2 Study of the Selective ATP-Competitive Inhibitor Ipatasertib (GDC-0068) in Patients with Tumors with AKT Mutation
(See required screening study ECOG-ACRIN EAY131)
Subprotocol EAY131-Z1K has reached its accrual goal and is, therefor permanently closed to accrual effective 11/13/20
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
NCT#02465060
(Click for More Info)
NCI COVID-19
Primary Category:
Treatment Protocols
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04387656
NCI COVID-19 is permanently closed to accrual, effective January 31, 2022.
NRG B-51
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#01872975
(Click for More Info)
NSABP B-51 is permanently closed to accrual on December 28, 2020.
The accrual goal for the Behaviorial and Health Outcomes (BAHO) Quality of Life component in the B-51 trial has been met. Therefore, effective August 6th, 2018, accrual will be closed to the QoL component. The B-51 trial remains open to accrual.
NRG B-55
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast, Breast Neoadjuvant
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Eligible for screening study DCP 001
NCT#02032823
(Click for More Info)
B-55 is closed to accrual effective April 29, 2019.
Closure of Part 1 and Part 2 Screening will occur on April 1, 2019 at 5:00 PM Eastern Time. Accrual to the NSABP B-55/BIG 6-13 trial will close on April 29, 2019 at 5:00 PM Eastern Time. Patients, who are in screening, must be randomized to the study by 5:00 PM on April 29, 2019.
Protocol Letter to Investigators AE Flowsheet-Physician AE Flowsheet-Nurse Or Coordinator
SWOG S2013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04871542
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Sarcoma
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A091401
Primary Category:
Treatment Protocols
Disease Category:
Sarcoma
Randomized Phase II Study of Nivolumab with or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma
NCT#02500797
(Click for More Info)
Effective Thursday, August 1, 2019, Alliance A091401 is permanently closed to new patient accrual.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Skin
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A091802
Primary Category:
Treatment Protocols
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
NCT#03944941
(Click for More Info)
ALLIANCE A091903
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma
(Click for More Info)
NCT#05111574
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
ECOG-ACRIN EA6134
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Eligible for screening study DCP 001
EA6134 is closed to accrual, effective September 30, 2021.
NCT#02224781
(Click for More Info)
ECOG-ACRIN EA6141
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
NCT#02339571
(Click for More Info)
This protocol has additional training requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective 10/08/21
ECOG-ACRIN EA6174
Primary Category:
Treatment Protocols
STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
NCT#03712605
(Click for More Info)
Eligible for screening study DCP 001
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH)
Eligible for screening study DCP 001
NCT#02465060
(Click for More Info)
Effective 11/23/20, PathGroup is temporarily suspending efforts to proactively identify and refer potentially eligible patients for enrollment in Step 0 via the Outside Assay process.
The protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at approved MATCH trial sites. Approved genetic testing laboratories and their date of inclusion in the outside assay process are:
- CARIS Life Sciences – 07/02/18
- CellNetix Pathology and Laboratories – 02/13/19
- Foundation Medicine – 07/02/18
- GenPath BioReference Laboratories – 08/03/18
- The Jackson Laboratory – 01/10/19
- NeoGenomics Laboratories – 07/02/18
- OmniSeq Laboratories – 07/16/18
- PathGroup – 10/29/18
- Quest Diagnostics Inc. – 05/20/19
- Strata Oncology – 08/03/18
- Tempus Laboratories – 07/16/18
The Biopsy consent form for this study is available upon request. Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.
(http://ecog-acrin.org/nci-match-eay131-designated-labs)
SWOG S1404
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Skin
A Phase III Randomized Trial Comparing Physician/Patient Choice of High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
Eligible for screening study DCP 001
NCT#02506153
(Click for More Info)
Step 1 (prestudy screening) of S1404 study has reached its accrual goal and will be permanently closed to accrual effective August 15, 2017 at 11:59 p.m. Pacific Time.
Step 2 (randomization) of S1404 will be permanently closed to accrual effective November 2, 2017 at 11:59 p.m. Pacific Time.
SWOG S1616
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti PD-L1 Agent
NCT#03033576
(Click for More Info)
S1616 is permanently closed to accrual effective July 15, 2020.
SWOG S1801
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
NCT#03698019
(Click for More Info)
S1801 is permanently closed to accrual, effective May 5, 2022, at 11:59pm Pacific Time.
SWOG S2000
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
(Click for More Info)
NCT#04511013
SWOG S2013
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Anal, Bladder, Breast, Breast DCIS, Breast Metastatic, Breast Neoadjuvant, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Lymphoma, Melanoma, Metastatic Melanoma, Pancreatic, Pancreatic Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Skin, Small Bowel, Stomach, Stomach Metastatic
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Eligible for screening study DCP 001
(Click for More Info)
NCT#04871542
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
Solid tumor or Hematologic Malignancy
ECOG-ACRIN EAQ172
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Solid tumor or Hematologic Malignancy
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Eligible for screening study DCP 001
(Click for More Info)
NCT#04438382
Thyroid
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
NCT#03249090
(Click for More Info)
Limited institution study – Only open to: Billings Clinic & Bozeman Health
Effective, October 25th, 2019, the CONTROL arm of AFT 39, is closed to accrual.
ALLIANCE A151804
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
NCT#04242095
(Click for More Info)
ALLIANCE A212102
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Bladder, Breast, Breast Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Leukemia, Liver, Lung, Lymphoma, Melanoma, Metastatic Melanoma, Multiple Myeloma, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Stomach, Thyroid
Blinded Reference Set For Multicancer Early Detection Blood Tests
(Click for More Info)
NCT#05334069
A212102 will temporarily suspend enrollment to white female participants under (<) age 60 without a cancer diagnosis, effective December 1, 2022, at 4:30 PM EST.
SWOG S2108CD
Primary Category:
Cancer Care Delivery
Disease Category:
Brain, Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Molecular Profiling, Neuroendocrine, Other, Sarcoma, Skin, Thyroid
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
Limited site participation. Open only to Kootenai Cancer Center.
(Click for More Info)
NCT#05455606
